Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies For Lead Candidate EB-373 Psilocin Prodrug Targeting Psychiatric Disorders
Portfolio Pulse from Benzinga Newsdesk
Enveric Biosciences has initiated GLP toxicology and safety pharmacology studies for its lead candidate EB-373, a psilocin prodrug targeting psychiatric disorders.
October 18, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Enveric Biosciences has started key studies for its lead candidate EB-373. This could potentially lead to regulatory approval and commercialization, positively impacting the company's stock.
The initiation of GLP toxicology and safety pharmacology studies is a significant step in the drug development process. If successful, it could lead to regulatory approval and commercialization of EB-373, which would likely have a positive impact on Enveric Biosciences' stock.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100